Therapy News and Research

RSS

Pharmaceutical companies working on nearly 100 life-changing medicines for HIV/AIDS

Medical News Today recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 100 life-changing medicines for diseases affecting people with HIV/AIDS, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

8 Jan 2010

MicroCHIPS raises $16.5 million to fund for diabetes and osteoporosis programs

MicroCHIPS, Inc., a developer of intelligent implant systems, has raised $16.5 million to fund its lead programs in diabetes and osteoporosis. Current investors Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital were joined by new investor InterWest Partners.

8 Jan 2010

Zebrafish publishes special issue on cancer biology

The zebrafish, a translucent fish often used as a model of human development and disease, offers unique advantages for studying the cause, growth, and spread of tumors using strategies and methods presented in the current "Cancer Biology" special issue of Zebrafish, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The entire issue is available free online at www.liebertpub.com/zeb

8 Jan 2010

Emerging Healthcare Solutions seeks business opportunities with new, patented T-Guide Platelet Function Analyzer

Emerging Healthcare Solutions, Inc. under their exclusive option agreement with Thrombovision, has begun due diligence to aggressively seek the establishment of business opportunities with the new patented T-Guide Platelet Function Analyzer.

8 Jan 2010

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

8 Jan 2010

Non-insulin-dependent patients with type 2 diabetes do not benefit from glucose self-monitoring

Contrary to the widely-held belief, there is no proof that non-insulin-dependent patients with type 2 diabetes benefit from glucose self-monitoring. Moreover, it remains unclear whether an additional benefit is displayed by the blood test compared to the urine test or vice versa, in other words, whether one or other of the tests might offer an advantage to patients.

8 Jan 2010

MUHC unveils new Lung Cancer Navigation Program

A diagnosis of lung cancer can come as a hard blow. The disease has one of the highest mortality rates of all cancers and the sheer complexity of therapy - often involving radiation, chemotherapy and surgery - can leave patients feeling confused and isolated. To help these patients navigate through the complicated treatment process and medical appointments, the MUHC has unveiled its new Lung Cancer Navigation Program (LCNP).

8 Jan 2010

Cell Medica signs R&D agreement with the Center for Cell and Gene Therapy

Cell Medica, a clinical cellular therapeutics company developing proven cell therapies which address important unmet clinical needs in oncology and infectious diseases, announced today the signing of an R&D agreement with the Center for Cell and Gene Therapy, a joint program of Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital, Houston, Texas.

8 Jan 2010

Young men with HIV infection have coronary atherosclerotic plaques: MGH study

A Massachusetts General Hospital (MGH) study has found that relatively young men with longstanding HIV infection and minimal cardiac risk factors had significantly more coronary atherosclerotic plaques - some involving serious arterial blockage - than did uninfected men with similar cardiovascular risk.

8 Jan 2010

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.

8 Jan 2010

University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD

University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.

8 Jan 2010

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1(TM) recombinant Fc-Factor VII fusion protein.

8 Jan 2010

Exercise, nutrition and hormone optimization are key to improve men's health issues

Grant Mansell was 46 and frustrated with his 300 pound physique, ensuing back pain, rising cholesterol, dependency on blood pressure medicine but most of all not enjoying life with his wife and children.

8 Jan 2010

University of Washington and Aegis Living to promote wellness programs

Healthy aging is more than just a saying at Aegis Living, a national leader in assisted living and Memory Care communities. Now it's working with faculty at University of Washington School of Medicine to make strides in the advancement of healthy aging through collaborative efforts started in Aegis Living's new Living 4 Life® program.

8 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Behavioral Innovations partners with insurance companies to mitigate financial burden on parents

Behavioral Innovations, the premier Dallas/Fort Worth provider of Applied Behavior Analysis (ABA) services for families of children with autism and other developmental disorders, announces its partnership with key insurance carriers to offer in-network insurance coverage for several ABA therapy programs. Behavioral Innovations is the first behavioral therapy center in the Metroplex to offer in-network insurance for select treatments - mitigating the financial burden on parents.

8 Jan 2010

Epigenetic diagnosis and therapies, a new strategy for treating cancer

A tumor's genetic profile is often useful when diagnosing and deciding on treatment for certain cancers, but inexplicably, genetically similar leukemias in different patients do not always respond well to the same therapy.

7 Jan 2010

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

The Cystinosis Research Foundation of Irvine, Calif., announced it awarded $1.75 million in 11 new grants to researchers in the United States, Canada, Belgium and Italy who are working to find a cure for cystinosis, a rare, deadly metabolic and genetic disease that afflicts about 500 children and young adults in the U.S. and 2,000 worldwide.

7 Jan 2010

High or low blood calcium levels linked to increased risk of premature death in kidney disease patients

Abnormally high or low blood calcium levels are linked to an increased chance of premature death in non-dialysis kidney disease patients, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

7 Jan 2010

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer.

7 Jan 2010

Therapy News and Research

Pharmaceutical companies working on nearly 100 life-changing medicines for HIV/AIDS

MicroCHIPS raises $16.5 million to fund for diabetes and osteoporosis programs

Zebrafish publishes special issue on cancer biology

Emerging Healthcare Solutions seeks business opportunities with new, patented T-Guide Platelet Function Analyzer

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Non-insulin-dependent patients with type 2 diabetes do not benefit from glucose self-monitoring

MUHC unveils new Lung Cancer Navigation Program

Cell Medica signs R&D agreement with the Center for Cell and Gene Therapy

Young men with HIV infection have coronary atherosclerotic plaques: MGH study

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Exercise, nutrition and hormone optimization are key to improve men's health issues

University of Washington and Aegis Living to promote wellness programs

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Behavioral Innovations partners with insurance companies to mitigate financial burden on parents

Epigenetic diagnosis and therapies, a new strategy for treating cancer

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

High or low blood calcium levels linked to increased risk of premature death in kidney disease patients

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News